Subscribe to read | Financial Times
arstechnica.com
News, analysis and comment from the Financial Times, the worldʼs leading global business publication
  • Dee@beehaw.orgEnglish
    8·
    1 year ago

    I wish there were some link to the study in the article, I tried to find it in the original Financial Times article but I got paywalled. This is really awesome though, I hope further research is shown because I’d love to hear more about how this differs from the previous methods of addressing Alzheimer’s.

    I guess

    Both lecanemab and donanemab are based on antibodies against amyloid, one of the toxic proteins that build up in the brain as Alzheimer’s proceeds, but they worked at different stages of the process, Oakley said. Lecanemab targets amyloid as it begins to form fibers in the brain while donanemab is active at a later stage, when the fibers have clumped together into larger accumulations of plaque.

    Is as close as we’re getting for now haha

    Edit: TheOakTree found the study for those who want to read more!

    Direct link to study.

      • Dee@beehaw.orgEnglish
        4·
        1 year ago

        From the Ars Article:

        The donanemab trial involved 1,736 participants

        From your link:

        Findings In this randomized clinical trial that included 1736 participants with early symptomatic Alzheimer disease and…

        I would be VERY surprised if this wasn’t the study in question 😂

        Thank you for finding that! I’ll read that over more when I get some time later!

        • TheOakTree@beehaw.orgEnglish
          4·
          1 year ago

          Now imagine if it were coincidence…

          Thankfully it’s not. Happy to see that alzheimer research is getting more interest though, it’s a scary condition.